{
    "id": 32761,
    "fullName": "BRCA2 R2287*",
    "impact": "nonsense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BRCA2 R2287* results in a premature truncation of the Brca2 protein at amino acid 2287 of 3418 (UniProt.org). R2287* results in a partial loss of exon 12 skipping and a 70% reduction in homology directed repair in cultured cells similar to wild-type Brca2 (PMID: 32046981), and therefore, is predicted lead to a loss of Brca2 protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 18117,
                    "pubMedId": 32046981,
                    "title": "Skipping nonsense to maintain function: the paradigm of BRCA2 exon 12.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32046981"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 675,
        "geneSymbol": "BRCA2",
        "terms": [
            "BRCA2",
            "BRCC2",
            "BROVCA2",
            "FACD",
            "FAD",
            "FAD1",
            "FANCD",
            "FANCD1",
            "GLM3",
            "PNCA2",
            "XRCC11"
        ]
    },
    "variant": "R2287*",
    "createDate": "03/11/2020",
    "updateDate": "03/12/2020",
    "referenceTranscriptCoordinates": {
        "id": 188395,
        "transcript": "NM_000059",
        "gDna": "chr13:g.32344575A>T",
        "cDna": "c.6859A>T",
        "protein": "p.R2287*",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20914,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Brca2-deficient cells expressing BRCA2 R2287* were partially sensitive to treatment with Talzenna (talazoparib) compared to wild-type Brca2 in culture, demonstrating reduced cell survival (PMID: 32046981).",
            "molecularProfile": {
                "id": 35398,
                "profileName": "BRCA2 R2287*"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18117,
                    "pubMedId": 32046981,
                    "title": "Skipping nonsense to maintain function: the paradigm of BRCA2 exon 12.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32046981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35398,
            "profileName": "BRCA2 R2287*",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 188395,
            "transcript": "NM_000059",
            "gDna": "chr13:g.32344575A>T",
            "cDna": "c.6859A>T",
            "protein": "p.R2287*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}